40
Participants
Start Date
July 31, 2007
Primary Completion Date
January 31, 2010
Study Completion Date
January 31, 2010
5-FU, Epirubicin, Cyclophosphamide, Docetaxel
3 cycles of FEC q3w, followed by 3 cycles of docetaxel q3w FEC: 5FU 500mg/m2 intravenous bolus D1, Epirubicin 100mg/m2 intravenous bolus D1, Cyclophosphamide 500mg/m2 intravenous bolus D1) every 21 days Docetaxel: (100mg/ m2 intravenous infusion) every 21 days
5-FU, Epirubicin, Cyclophosphamide, Docetaxel, Zoledronic acid
3 cycles of FEC q3w, followed by 3 cycles of docetaxel q3w FEC: 5FU 500mg/m2 intravenous bolus D1, Epirubicin 100mg/m2 intravenous bolus D1, Cyclophosphamide 500mg/m2 intravenous bolus D1) every 21 days Docetaxel: (100mg/ m2 intravenous infusion) every 21 days Zoledronic acid: 4mg intravenous infusion Day 2, AFTER FIRST CYCLE CHEMOTHERAPY ONLY
Sheffield Teaching Hospitals NHS Foundation Trust / Weston Park Hospital, Sheffield
University of Sheffield
OTHER
Sheffield Teaching Hospitals NHS Foundation Trust
OTHER